Data Storage And 2 Other US Penny Stocks To Watch

As U.S. stock markets remain relatively stable with the major indices showing little change, investors are increasingly looking towards alternative investment opportunities like penny stocks. Despite being a term from earlier market days, penny stocks continue to represent smaller or less-established companies that can offer unique opportunities for growth and value. By focusing on those with strong financial foundations and potential for expansion, investors may find promising prospects in this often-overlooked segment of the market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Inter & Co (NasdaqGS:INTR)	$4.43	$1.94B	★★★★☆☆
BAB (OTCPK:BABB)	$0.86	$6.25M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$144.14M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.89	$87.66M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.24	$8.83M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.49	$49.17M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9113	$81.96M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.84	$410.03M	★★★★☆☆

Click here to see the full list of 701 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Data Storage (NasdaqCM:DTST)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Data Storage Corporation offers data management and cloud solutions both in the United States and internationally, with a market cap of $31.56 million.

Operations: The company's revenue is primarily derived from its Cloudfirst Technologies segment, which accounts for $13.60 million, and Nexxis Inc, contributing $1.20 million.

Market Cap: $31.56M

Data Storage Corporation, with a market cap of US$31.56 million, is actively seeking acquisitions to enhance its operations and expand its reach. The company reported third-quarter sales of US$5.81 million, slightly down from the previous year, with net income also seeing a decline. Despite this, Data Storage has become profitable in the past year and forecasts suggest strong earnings growth ahead. The management team is seasoned and experienced, contributing to strategic initiatives like European expansion under new leadership. While the stock has experienced high volatility recently and shareholder dilution occurred last year, it remains debt-free with sufficient short-term assets covering liabilities.

• Click here and access our complete financial health analysis report to understand the dynamics of Data Storage.
• Examine Data Storage's earnings growth report to understand how analysts expect it to perform.

Kentucky First Federal Bancorp (NasdaqGM:KFFB)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Kentucky First Federal Bancorp, with a market cap of $23.45 million, operates as the holding company for First Federal Savings and Loan Association of Hazard, Kentucky, and Frankfort First Bancorp, Inc.

Operations: The company generates revenue of $7.48 million from its financial service operations.

Market Cap: $23.45M

Kentucky First Federal Bancorp, with a market cap of US$23.45 million, reported net interest income of US$1.87 million for the first quarter ended September 30, 2024, showing improvement from the previous year despite an overall net loss of US$0.015 million. The company has primarily low-risk funding through customer deposits and maintains an appropriate level of non-performing loans at 1.3%. However, it remains unprofitable with a negative return on equity and has faced challenges such as delayed SEC filings and significant losses in the past fiscal year. The board is experienced with an average tenure of 16.9 years.

• Navigate through the intricacies of Kentucky First Federal Bancorp with our comprehensive balance sheet health report here.
• Gain insights into Kentucky First Federal Bancorp's historical outcomes by reviewing our past performance report.

Exagen (NasdaqGM:XGN)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Exagen Inc. develops and commercializes testing products under the AVISE brand in the United States, with a market cap of $80.25 million.

Operations: Exagen generates revenue from its Diagnostic Kits and Equipment segment, totaling $55.75 million.

Market Cap: $80.25M

Exagen Inc., with a market cap of US$80.25 million, is navigating the penny stock landscape by leveraging its AVISE brand diagnostic products, generating US$55.75 million in revenue. Despite being unprofitable and experiencing shareholder dilution, Exagen shows potential through recent advancements in biomarker technology for autoimmune diseases like SLE and RA, pending regulatory approval. The company maintains a strong cash position with sufficient runway for over three years and trades at a significant discount to estimated fair value. However, it faces challenges such as high volatility and increased debt levels over the past five years.

• Jump into the full analysis health report here for a deeper understanding of Exagen.
• Review our growth performance report to gain insights into Exagen's future.

Key Takeaways

• Gain an insight into the universe of 701 US Penny Stocks by clicking here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com